Immunization, Vaccines and Biologicals

Status of public health impact and health economic analyses for malaria vaccines

7-8 May 2013, WHO HQ, Geneva, switzerland


A first consultation was held on this topic in March 2011. That meeting stimulated major additional work by multiple modelling and health economics groups. By late 2014, WHO will need to perform an assessment of the health economic analyses available to support policy recommendations for malaria vaccines.


  • Assess progress made on public health impact and health economic analyses by the leading groups globally including GSK Biologicals, Swiss Tropical Public Health Institute, Imperial College and Intellectual Ventures.
  • Assess status of new groups such as Wellcome-Mahidol University, Bangkok, Thailand.

Expected outcomes

  • Agreement with WHO Joint Technical Expert Group (JTEG) and IVIR-AC members on the status and role of health economic analyses in the policy recommendation process for the RTS,S/AS01 malaria vaccine
  • Decision on whether WHO should undertake targeted activities in this area, such as a malaria vaccine costing tool for implementation using additional immunization visits
  • Decision on whether a formal comparative assessment of malaria vaccine health economic tools/models should occur, and if yes, agree a workplan to conduct such an assessment.